SCHEMBL2226580

SCHEMBL2226580

CCc1cccn2c(-c3nc(N[C@@H](C)c4ccc(C(O)C5CCN(C)CC5)cc4)ncc3C#N)cnc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 4/20 0.38
IGF1R P08069 3/20 0.36
IDH1 O75874 5/20 0.35
CDK2 P24941 5/20 0.35
CCNT1 O60563 2/20 0.33
CDK1 P06493 2/20 0.33
CCNB1 P14635 2/20 0.33
CCNA2 P20248 2/20 0.33
CDK7 P50613 2/20 0.33
CDK9 P50750 2/20 0.33
CCNH P51946 2/20 0.33
ACACB O00763 2/20 0.33
JUN P05412 2/20 0.32
MAPK8 P45983 2/20 0.32
MAPK9 P45984 2/20 0.32
MAPK10 P53779 1/20 0.32
TYRO3 Q06418 2/20 0.32
MERTK Q12866 2/20 0.32
IDH2 P48735 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197910 0.94 PLK1 (0.38) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2195522 0.94 PLK1 (0.39) PLK1IGF1RIDH1CDK2CDK1
SCHEMBL2227194 0.93 TYRO3 (0.39) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2196677 0.92 PLK1 (0.39) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL19951509 0.92 PLK1 (0.39) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2197739 0.92 PLK1 (0.39) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2198015 0.92 PLK1 (0.39) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2198070 0.92 PLK1 (0.38) PLK1IGF1RIDH1CDK2CCNT1
SCHEMBL2198896 0.91 PLK1 (0.38) PLK1IGF1RIDH1CDK2ACACB
SCHEMBL2195412 0.91 IGF1R (0.36) PLK1IGF1RIDH1CDK2ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114942-B1 NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS MSD KK (JP) 2012-10-31 EP disclosed
US-7977336-B2 Aminopyrimidine derivatives as PLK1 inhibitors BANYU PHARMACEUTICAL CO. LTD (JP) 2011-07-12 US disclosed
EP-2114942-A1 NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-11-11 EP disclosed
EP-2116543-A1 NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-11-11 EP disclosed
US-20080305081-A1 Novel aminopyrimidine derivatives as PLK1 inhibitors BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-12-11 US disclosed
WO-2008081910-A1 NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305081-A1 Novel aminopyrimidine derivatives as PLK1 inhibitors PLK1, AURKA, CDK1 PLK1 1/4885IGF1R 812/4885IDH1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.